Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

Manish A. Shah, MD, discusses an optimal sequencing strategy in gastroesophageal cancer.

Scott T. Tagawa, MD, MS, discusses the results of the phase I dose-escalation trial, the advantages of using an alpha emitter and a monoclonal antibody, and the possibility of combining the modality with other classes of agents in prostate cancer.

Scott T. Tagawa, MD, MS, discusses the utility of beta and alpha emitters in targeting PSMA in prostate cancer.

Manish A. Shah, MD, discusses how the management of patients with gastric/GEJ cancer has evolved over the last several years.

Scott T. Tagawa, MD, MS, discusses the safety profile of novel monoclonal antibody 225Ac-J591 in metastatic castration-resistant prostate cancer.

We recently traveled to Brooklyn, New York, for a State of the Science Summit™ on Gastrointestinal Cancer, which featured insights from Weill Cornell Medical Center and Montefiore Medical Center faculty.

Kathryn E. Hudson, MD, and Jeff Yorio, MD, discuss when it is appropriate to wait for testing before starting therapy, the accuracy of tumor and liquid biopsies, as well as optimal sequencing strategies when managing patients with brain metastases.

Scott T. Tagawa, MD, MS, discusses preliminary data with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Richard R. Furman, MD, discusses acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Ashish Saxena, MD, PhD, discusses the future of next-generation ALK inhibitors in non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses available next-generation ALK inhibitors in non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses the importance of biomarker testing for stage IV ALK-positive non–small cell lung cancer.

Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.

Manuel Hidalgo Medina, MD, PhD, discusses microsatellite instability and germline testing patients with pancreatic cancer.

Ashish Saxena, MD, PhD, discusses the treatment landscape of ALK-positive non–small cell lung cancer.

Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Manuel Hidalgo Medina, MD, PhD, discusses treatment considerations in pancreatic cancer.

Allyson Ocean, MD, discusses the impact of the phase III PRODIGE 24/CCTG PA.6 trial on patients with pancreatic cancer.

Richard R. Furman, MD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Allyson Ocean, MD, discusses the use of circulating tumor DNA in pancreatic cancer.

Manish A. Shah, MD, discusses biomarkers in gastric and gastroesophageal junction cancer.

Manuel Hidalgo Medina, MD, PhD, discusses the emergence of neoadjuvant chemotherapy and radiation in pancreatic cancer.

Allyson Ocean, MD, discusses efforts to improve early detection rates in pancreatic cancer.

Brendon Stiles, MD, discusses considerations for surgery in lung cancer.

Lukas E. Dow, PhD, discusses ongoing research evaluating Wnt as a potential target in colorectal cancer.

Manish A. Shah, MD, discusses ongoing research evaluating immunotherapy and other novel treatments in advanced gastric and gastroesophageal junction cancer.

Luke Dow, PhD, discusses phase I trials targeting the Wnt signaling pathway in colorectal cancer.

Manish A. Shah, MD, discusses the use of trastuzumab biosimilars in gastric cancer.